CoChat

Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma

Open access

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

Introduction We describe the imaging findings encountered in GBM patients receiving immune checkpoint blockade and assess the potential of quantitative MRI biomarkers to differentiate patients who derive therapeutic benefit from those who do not.Methods A retrospective analysis was performed on longitudinal MRIs obtained on recurrent GBM patients enrolled on clinical trials. Among 10 patients with analyzable data, bidirectional diameters were measured on contrast enhanced T1 (pGd-T1WI) and volumes of interest (VOI) representing measurable abnormality suggestive of tumor were selected on pGdT1WI (pGdT1 VOI), FLAIR-T2WI (FLAIR VOI), and ADC maps. Intermediate ADC (IADC) VOI represented voxels within the FLAIR VOI having ADC in the range of highly cellular tumor (0.7-1.1 × 10-3 mm 2/s) (IADC VOI). Therapeutic benefit was determined by tissue pathology and survival on trial. IADC VOI, pGdT1 VOI, FLAIR VOI, and RANO assessment results were correlated with patient benefit.Results Five patients were deemed to have received therapeutic benefit and the other five patients did not. The average time on trial for the benefit group was 194 days, as compared to 81 days for the no benefit group. IADC VOI correlated well with the presence or absence of clinical benefit in 10 patients. Furthermore, pGd VOI, FLAIR VOI, and RANO assessment correlated less well with response.Conclusion MRI reveals an initial increase in volumes of abnormal tissue with contrast enhancement, edema, and intermediate ADC suggesting hypercellularity within the first 0-6 months of immunotherapy. Subsequent stabilization and improvement in IADC VOI appear to better predict ultimate therapeutic benefit from these agents than conventional imaging.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00234-016-1769-8

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. Reardon DA Gokhale PC Klein SR 2015 Glioblastomaeradication following immune checkpoint blockade in an orthotopic, Immunocompetentmodel Cancer Immunol Res 4 124 135 26546453 · DOI · Paper page

Cited by

See all 64

Metadata

Authors
Qin, L., Li, X., Stroiney, A., Qu, J., Helgager, J., Reardon, D. A., & Young, G. S.
Affiliations
  • Harvard University (US)
  • Brigham and Women's Hospital (US)
  • Northeastern University (US)
Corresponding author
  • Reardon, David A.
  • Young, Geoffrey S.
Venue
Neuroradiology
Published
2017-01-09
Volume
59
Issue
2
Pages
135-145
ISSN
  • 0028-3940 (ISSN-L)
  • 1432-1920
OpenAlex
W2571209703
Cited by
64
References
34
Citations by year
2025: 3 · 2024: 3 · 2023: 8 · 2022: 6 · 2021: 10 · 2020: 8 · 2019: 12 · 2018: 9 · 2017: 5
FWCI
5.34
Type
journal article
Language
en
Open access
Locations
  • Neuroradiology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Bristol-Myers Squibb
  • Momenta Pharmaceuticals
  • National Institutes of Health (2r25ca174650-11)
  • Genentech
  • National Cancer Institute (#R25CA174650)
Topics
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
Keywords
recurrent glioblastoma, immune checkpoint blockade, PD-1 inhibitors, immunotherapy response prediction, quantitative MRI biomarkers, apparent diffusion coefficient, contrast-enhanced T1-weighted imaging, FLAIR, treatment response prediction
MeSH terms
Ipilimumab, Nivolumab, Antibodies, Monoclonal, Antineoplastic Agents, Brain Neoplasms, Contrast Media, Female, Glioblastoma, Humans, Image Interpretation, Computer-Assisted, Immunotherapy, Magnetic Resonance Imaging, Male, Neoplasm Recurrence, Local, Retrospective Studies, Biomarkers, Tumor, Survival Rate, Treatment Outcome, Neoplasm Grading, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.